Atara Biotherapeutics Inc (NASDAQ:ATRA) Receives Average Rating of “Buy” from Brokerages

Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) have received a consensus rating of “Buy” from the eleven brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $43.40.

Several brokerages have weighed in on ATRA. ValuEngine downgraded Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 17th. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 16th. Cowen restated a “buy” rating on shares of Atara Biotherapeutics in a research note on Tuesday, July 16th. Canaccord Genuity restated a “buy” rating and issued a $70.00 price target on shares of Atara Biotherapeutics in a research note on Monday, July 1st. Finally, Citigroup set a $14.00 price target on Atara Biotherapeutics and gave the company a “hold” rating in a research note on Monday, August 12th.

In related news, CEO Isaac E. Ciechanover sold 5,850 shares of Atara Biotherapeutics stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $23.09, for a total transaction of $135,076.50. Following the completion of the transaction, the chief executive officer now directly owns 332,243 shares of the company’s stock, valued at $7,671,490.87. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Eric Dobmeier acquired 2,000 shares of Atara Biotherapeutics stock in a transaction that occurred on Thursday, June 27th. The shares were purchased at an average cost of $19.50 per share, with a total value of $39,000.00. Following the completion of the acquisition, the director now owns 16,000 shares of the company’s stock, valued at approximately $312,000. The disclosure for this purchase can be found here. 7.00% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of ATRA. Maverick Capital Ltd. raised its holdings in Atara Biotherapeutics by 156.4% during the second quarter. Maverick Capital Ltd. now owns 2,232,476 shares of the biotechnology company’s stock worth $44,895,000 after purchasing an additional 1,361,712 shares during the last quarter. FMR LLC raised its holdings in shares of Atara Biotherapeutics by 21.7% in the first quarter. FMR LLC now owns 6,417,956 shares of the biotechnology company’s stock worth $255,114,000 after acquiring an additional 1,143,787 shares during the last quarter. Morgan Stanley raised its holdings in shares of Atara Biotherapeutics by 55.8% in the second quarter. Morgan Stanley now owns 1,997,538 shares of the biotechnology company’s stock worth $40,171,000 after acquiring an additional 715,077 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Atara Biotherapeutics by 53.8% in the first quarter. JPMorgan Chase & Co. now owns 1,917,903 shares of the biotechnology company’s stock worth $76,237,000 after acquiring an additional 671,216 shares during the last quarter. Finally, Baupost Group LLC MA raised its holdings in shares of Atara Biotherapeutics by 9.7% in the second quarter. Baupost Group LLC MA now owns 7,000,000 shares of the biotechnology company’s stock worth $140,770,000 after acquiring an additional 619,481 shares during the last quarter.

Shares of ATRA stock traded up $0.71 during midday trading on Friday, hitting $14.06. The company had a trading volume of 848,000 shares, compared to its average volume of 960,998. The company’s 50 day simple moving average is $15.88 and its 200 day simple moving average is $28.19. Atara Biotherapeutics has a 52-week low of $11.89 and a 52-week high of $43.95. The stock has a market cap of $755.30 million, a price-to-earnings ratio of -2.67 and a beta of 2.08. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.80 and a quick ratio of 9.96.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.45) by ($0.15). Analysts anticipate that Atara Biotherapeutics will post -5.71 EPS for the current year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Story: Why is Cost of Capital Important?

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.